Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Target Price at $50.40

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $50.40.

A number of equities research analysts have recently weighed in on TWST shares. Guggenheim restated a “buy” rating and issued a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird dropped their price objective on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group dropped their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Finally, Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th.

Twist Bioscience Trading Down 1.7%

Shares of Twist Bioscience stock opened at $30.39 on Tuesday. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -8.99 and a beta of 2.54. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $28.46 and a 12-month high of $60.90. The firm’s 50-day moving average price is $37.64 and its two-hundred day moving average price is $43.24.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. On average, analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,042 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $189,831.30. Following the completion of the sale, the chief executive officer now owns 655,432 shares in the company, valued at approximately $24,677,014.80. The trade was a 0.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Dennis Cho sold 689 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $25,940.85. Following the sale, the insider now owns 110,849 shares of the company’s stock, valued at $4,173,464.85. This trade represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,991 shares of company stock worth $742,654 in the last quarter. 3.01% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc boosted its holdings in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Banque Transatlantique SA purchased a new position in Twist Bioscience during the 4th quarter worth $43,000. Finally, GF Fund Management CO. LTD. purchased a new position in Twist Bioscience during the 4th quarter worth $58,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.